腹腔镜非肿瘤性内脏手术后疼痛管理中的区域麻醉:系统综述与Meta分析
该系统综述与Meta分析纳入82项试验,评估区域麻醉用于成人腹腔镜非肿瘤性内脏手术后疼痛管理的效果。周围区域麻醉联合全麻较单用全麻可能轻度降低24小时静息疼痛(MD -0.72分,低确定性证据),但无临床相关性;椎管内区域镇痛联合全麻可能临床相关地降低24小时静息疼痛(MD -1.19分,低确定性证据),但增加阻滞相关不良事件风险(RR 5.11,极低确定性证据)。
要点
- 周围区域麻醉联合全麻较单用全麻可能轻度降低24小时静息疼痛(MD -0.72分),但无临床相关性。
- 椎管内区域镇痛联合全麻较单用全麻可能临床相关地降低24小时静息疼痛(MD -1.19分)。
- 椎管内区域镇痛联合全麻可能增加阻滞相关不良事件风险(RR 5.11,95%CI 1.13至23.03)。
核心结论
- 该Meta分析证实区域麻醉可能是腹腔镜内脏手术多模式术后镇痛的重要组成部分,例如用于有严重术后疼痛风险的患者,且不同手术方式和设置间差异很大。
- 需要进一步研究评估佐剂的使用以及区域麻醉在ERAS方案中的额外获益。
研究设计与样本
- 系统综述与Meta分析,采用GRADE评估证据质量,纳入82项试验。
- 方案注册号:PROSPERO CRD42021258281。
主要发现
- 周围区域麻醉联合全麻对比单用全麻可能轻度降低24小时静息疼痛强度(MD -0.72分;95%CI -0.91至-0.54;I²=97%;低确定性证据),但无临床相关性。
- 周围区域麻醉联合全麻对比单用全麻对24小时活动时疼痛强度的影响证据非常不确定(MD -0.8分;95%CI -1.17至-0.42;I²=99%;极低确定性证据)。
- 椎管内区域镇痛联合全麻对比单用全麻可能临床相关地降低24小时静息疼痛强度(MD -1.19分;95%CI -1.99至-0.39;I²=97%;低确定性证据)。
- 椎管内区域镇痛联合全麻对比单用全麻对24小时活动时疼痛强度的效果不确定(MD -1.13分;95%CI -2.31至0.06;I²=95%;极低确定性证据)。
- 椎管内区域镇痛联合全麻对比单用全麻可能增加阻滞相关不良事件风险(RR 5.11;95%CI 1.13至23.03;I²=0%;极低确定性证据),但证据不确定。
关键数值与推荐
- 周围区域麻醉联合全麻对比单用全麻:24小时静息疼痛MD -0.72分(95%CI -0.91至-0.54;I²=97%;低确定性证据),无临床相关性。
- 椎管内区域镇痛联合全麻对比单用全麻:24小时静息疼痛MD -1.19分(95%CI -1.99至-0.39;I²=97%;低确定性证据),有临床相关性。
- 椎管内区域镇痛联合全麻对比单用全麻:阻滞相关不良事件RR 5.11(95%CI 1.13至23.03;I²=0%;极低确定性证据)。
临床怎么用
- 作者认为区域麻醉可能是腹腔镜内脏手术多模式术后镇痛的重要组成部分,例如用于有严重术后疼痛风险的患者。
- 作者指出不同手术方式和设置间差异很大。
- 作者建议需要进一步研究评估佐剂的使用以及区域麻醉在ERAS方案中的额外获益。
局限性
- 周围区域麻醉联合全麻对比单用全麻对24小时静息疼痛强度的证据为低确定性(I²=97%)。
- 周围区域麻醉联合全麻对比单用全麻对24小时活动时疼痛强度的证据为极低确定性(I²=99%)。
- 椎管内区域镇痛联合全麻对比单用全麻对24小时活动时疼痛强度的效果不确定(95%CI -2.31至0.06;I²=95%;极低确定性证据)。
- 椎管内区域镇痛联合全麻对比单用全麻增加阻滞相关不良事件风险的证据不确定(RR 5.11;95%CI 1.13至23.03;I²=0%;极低确定性证据)。
- 需要进一步研究评估佐剂的使用以及区域麻醉在ERAS方案中的额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative pain management following laparoscopic, non-oncological visceral surgery in adults is challenging. Regional anaesthesia could be a promising component in multimodal pain management. METHODS: We performed a systematic review and meta-analysis with GRADE assessment. Primary outcomes were postoperative acute pain intensity at rest/during movement after 24 h, the number of patients with block-related adverse events and the number of patients with postoperative paralytic ileus. RESULTS: 82 trials were included. Peripheral regional anaesthesia combined with general anaesthesia versus general anaesthesia may result in a slight reduction of pain intensity at rest at 24 h (mean difference (MD) - 0.72 points; 95% confidence interval (CI) - 0.91 to - 0.54; I2 = 97%; low-certainty evidence), which was not clinically relevant. The evidence is very uncertain regarding the effect on pain intensity during activity at 24 h (MD -0.8 points; 95%CI - 1.17 to - 0.42; I2 = 99%; very low-certainty evidence) and on the incidence of block-related adverse events. In contrast, neuraxial regional analgesia combined with general anaesthesia (versus general anaesthesia) may reduce postoperative pain intensity at rest in a clinical relevant matter (MD - 1.19 points; 95%CI - 1.99 to - 0.39; I2 = 97%; low-certainty evidence), but the effect is uncertain during activity (MD - 1.13 points; 95%CI - 2.31 to 0.06; I2 = 95%; very low-certainty evidence). There is uncertain evidence, that neuraxial regional analgesia combined with general anaesthesia (versus general anaesthesia) increases the risk for block-related adverse events (relative risk (RR) 5.11; 95%CI 1.13 to 23.03; I2 = 0%; very low-certainty evidence). CONCLUSION: This meta-analysis confirms that regional anaesthesia might be an important part of multimodal postoperative analgesia in laparoscopic visceral surgery, e.g. in patients at risk for severe postoperative pain, and with large differences between surgical procedures and settings. Further research is required to evaluate the use of adjuvants and the additional benefit of regional anaesthesia in ERAS programmes. PROTOCOL REGISTRATION: PROSPERO CRD42021258281.
引用
- Lohmöller K, Carstensen V, Pogatzki-Zahn EM, et al. Regional anaesthesia for postoperative pain management following laparoscopic, visceral, non-oncological surgery a systematic review and meta-analysis. Surg Endosc. 2024. PMID: 38307961. doi:10.1007/s00464-023-10667-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。